These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32328797)

  • 1. Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system.
    Cotter TG; Dong L; Holmen J; Gilroy R; Krong J; Charlton M
    J Gastroenterol; 2020 Jul; 55(7):722-730. PubMed ID: 32328797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
    Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
    Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Widman L; Stål P; Hultcrantz R; Kechagias S; Henriksson M
    Clin Gastroenterol Hepatol; 2020 Jun; 18(7):1592-1599.e8. PubMed ID: 31634581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database.
    Allen AM; Van Houten HK; Sangaralingham LR; Talwalkar JA; McCoy RG
    Hepatology; 2018 Dec; 68(6):2230-2238. PubMed ID: 29774589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.
    Terai S; Buchanan-Hughes A; Ng A; Lee IH; Hasegawa K
    J Gastroenterol; 2021 Mar; 56(3):274-284. PubMed ID: 33496858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases.
    Wong RJ; Kachru N; Martinez DJ; Moynihan M; Ozbay AB; Gordon SC
    J Clin Gastroenterol; 2021 Nov-Dec 01; 55(10):891-902. PubMed ID: 32815873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA.
    Nguyen AL; Park H; Nguyen P; Sheen E; Kim YA; Nguyen MH
    Dig Dis Sci; 2019 Mar; 64(3):698-707. PubMed ID: 30327963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany.
    Canbay A; Kachru N; Haas JS; Meise D; Ozbay AB; Sowa JP
    Ann Transl Med; 2021 Apr; 9(8):615. PubMed ID: 33987313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease.
    Younossi ZM; Zheng L; Stepanova M; Henry L; Venkatesan C; Mishra A
    J Clin Gastroenterol; 2015 Mar; 49(3):222-7. PubMed ID: 24637730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies.
    Golabi P; Owrangi S; Younossi ZM
    Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1():S1-S9. PubMed ID: 38813821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
    Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
    Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic Fatty Liver Disease Associates With Increased Overall Mortality and Death From Cancer, Cardiovascular Disease, and Liver Disease in Women but Not Men.
    Hwang YC; Ahn HY; Park SW; Park CY
    Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1131-1137.e5. PubMed ID: 29158157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
    Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
    Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries.
    Holmer M; Melum E; Isoniemi H; Ericzon BG; Castedal M; Nordin A; Aagaard Schultz N; Rasmussen A; Line PD; Stål P; Bennet W; Hagström H
    Liver Int; 2018 Nov; 38(11):2082-2090. PubMed ID: 29630771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.
    Estes C; Razavi H; Loomba R; Younossi Z; Sanyal AJ
    Hepatology; 2018 Jan; 67(1):123-133. PubMed ID: 28802062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease burden: Australia, 2019-2030.
    Adams LA; Roberts SK; Strasser SI; Mahady SE; Powell E; Estes C; Razavi H; George J
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1628-1635. PubMed ID: 32048317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients.
    C Gordon S; Fraysse J; Li S; Ozbay AB; Wong RJ
    Am J Gastroenterol; 2020 Apr; 115(4):562-574. PubMed ID: 31833859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
    Younossi ZM; Tampi RP; Racila A; Qiu Y; Burns L; Younossi I; Nader F
    Diabetes Care; 2020 Feb; 43(2):283-289. PubMed ID: 31658974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population.
    Sayiner M; Arshad T; Golabi P; Paik J; Farhat F; Younossi ZM
    Hepatol Int; 2020 Jul; 14(4):556-566. PubMed ID: 32300995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.